Skip to main content

Bio-Rad Laboratories, Inc.

BIO.B
Exchange
NYSE
Industry
Laboratory Analytical Instruments
SEC CIK
0000012208

No open-market purchases or sales by Bio-Rad Laboratories, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Other share classesBIO

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026
0
13F valueReported value at the end of Q2 2026
$0
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding BIO.B, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding BIO.B at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Bio-Rad Laboratories, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 13, 2026 (view filing)May 112 daysEngelhardt Eva AnetteEVP, President, CDGSSaleBio-Rad A Common Stock−550$246.54−$135.6K−61.4%346 after
Nov 10, 2025 (view filing)Nov 64 daysBarry JamesEVP, President, LSGSSaleBio-Rad A Common Stock−699.87$306.18−$214.3K−57.9%509.68 after
Mar 18, 2025 (view filing)Mar 144 daysCrowley MichaelEVP, GBL Commercial OperationsSSaleBio-Rad A Common Stock−3.00K$247.06−$741.2K−26.9%8.17K after
Sep 10, 2024 (view filing)Sep 64 daysLast Andrew J.EVP, Chief Operating OfficerSSaleBio-Rad A Common Stock−3.00K$329.94−$989.8K−28.4%7.56K after
Sep 4, 2024 (view filing)Sep 4Same dayBarry JamesEVP, President, LSGSSaleBio-Rad A Common Stock−623$330.49−$205.9K−81.0%146.56 after
Jun 14, 2024 (view filing)Jun 131 dayCrowley MichaelEVP, GBL Commercial OperationsSSaleBio-Rad A Common Stock−369$281.91−$104.0K−5.3%6.57K after
May 1, 2024 (view filing)May 3, 2023364 daysLateSchwartz Steven D10% OwnerSSaleBio-Rad A Common Stock−320$463.86−$148.4K−17.6%1.50K after
Feb 29, 2024 (view filing)Feb 281 dayErnst Timothy SEVP, General Counsel & SecSSaleBio-Rad A Common Stock−2.50K$330.55−$826.4K−42.4%3.40K after
Feb 28, 2024 (view filing)Feb 271 dayCrowley MichaelEVP, GBL Commercial OperationsSSaleBio-Rad A Common Stock−3.00K$336.00−$1.01M−30.2%6.94K after
Dec 12, 2023 (view filing)Dec 12Same dayWright DaraEVP, President, CDGSSaleBio-Rad A Common Stock−1.20K$299.16−$359.0K−44.5%1.50K after

Top 10 13F holders, Q2 2026

The largest institutional positions in Bio-Rad Laboratories, Inc. at the end of Q2 2026; share changes are against Q1 2026.

View all: Top 10 13F holders, Q2 2026

No institution reported holding BIO.B in 13F filings for Q2 2026.